Optimal Cutoff Age for Predicting Mortality Associated with Differentiated Thyroid Cancer

Su-jin Kim1,2,3, Jun Pyo Myong4*, Kyunsuk Suh5, Kyu Eun Lee1,2,3*, Yeo-Kyu Youn1,2,3

1 Department of Surgery, Seoul National University Hospital & College of Medicine, Seoul, Korea, 2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, 3 Division of Surgery, Thyroid Center, Seoul National University Hospital, Seoul, Korea, 4 Department of Occupational and Environmental Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University, Seoul, Korea, 5 Department of Surgery, Mount Sinai Beth Israel Hospital, Icahn School of Medicine at Mount Sinai, New York, United States of America

* medical001@catholic.ac.kr (JPM); kyueunlee@snu.ac.kr (KEL)

Abstract

Patient’s age at the time of diagnosis is an important prognostic factor for differentiated thyroid cancer (DTC) as reflected in various staging and risk stratification systems. However, discrepancies exist among the different staging systems on an optimal cut-off age for predicting the clinical outcome of patients with DTC. To determine the age at diagnosis most predictive of clinical outcomes of DTC, a population-based cohort study was performed composed of 35,323 patients with DTC between 1988 and 2010 using the Surveillance, Epidemiology, and End Results (SEER) database. The Youden index J was used to determine the most predictive age-at-diagnosis for thyroid-cancer-specific death. The multivariate Cox proportional hazards model was used to determine the hazard ratios (HRs) for each age group. With a median follow-up of 5.4 years (range, 0–22.9 years), DTC-associated mortality was 1.5% (n = 533) and the rate of death from overall cause was 7.0% (n = 2482). The optimal cutoff age at diagnosis for thyroid-cancer-specific death was 57. Multivariate analysis found that the age-at-diagnosis is the most prognostic factor for thyroid-cancer-specific death (HR 10.02, 95% CI 8.18–12.28). Age at diagnosis is the most important prognostic factor for DTC patients. Based on our analysis, age at diagnosis of 57 might be the optimal predictor of thyroid-cancer-specific death. This finding might be used as consideration in revision of the risk stratification system for treatment of DTC patients.

Introduction

Thyroid cancer is the most common type of endocrine malignancy, and its incidence worldwide has rapidly increased during the last 3 decades [1, 2]. The majority of thyroid cancers are differentiated thyroid cancer (DTC), which is histologically subdivided into papillary thyroid cancer (80%–85%), and follicular thyroid cancer (10%–15%). Although most DTCs are
indolent, with an excellent prognosis, some DTCs can spread, metastasize, recur, and eventually lead to death [1]. Therefore, risk-stratified treatment and surveillance are important for DTC management.

Unlike the other malignancies, patient’s age at the time of diagnosis is an important criterion as a prognostic determinant in most DTC staging systems [3–10]. However, significant variability exists among the systems. Certain staging systems use the age-at-diagnosis as a continuous variable [3–7] while other systems use it as a categorical variable with various cutoff ages [8–10]. Recent studies have evaluated the relationship between the age-at-diagnosis and the prognosis of patients with DTC, and attempted to establish the age that was most predictive of cancer-specific death [11,12]. However, because the study sample sizes were small, determining the optimal prognostic age were limited given the low incidence of DTC-related deaths.

Therefore, the aim of this study was to determine the age at the time of diagnosis that was most predictive of DTC-specific death using a population-based cohort. For the analysis, the Youden index \( J \) was utilized along with the Kaplan-Meier analysis, log-rank test, and multivariate analysis using the Cox proportional hazards model.

### Materials and Methods

#### Ethics statement

The study design was approved by the Institutional Review Board of Seoul St. Mary’s Hospital, Korea (approval ID: KC14EISI0433). The dataset of SEER was openly accessed database. Cancer diagnoses are reportable diseases to the cancer registries (no consent required), including those that provide data to SEER. Therefore, the authors can access the processed publically available data from web site for SEER. Patients’ records were anonymized and de-identified prior to the analysis.

#### SEER database and eligible study population

The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) collects data on cancer incidence and survival from about 28% of the population of the United States. The SEER database includes demographic (age at diagnosis, gender, race), clinical (primary tumor site, tumor size and extent, operation type, lymph node involvement, distant metastasis), and prognostic (cancer-specific cause of death and overall cause of death) data. Ongoing quality control and quality improvement is performed by the SEER Program to ensure the collection of high-quality data. Additional details regarding the methods and design of the SEER Program, and the participating states have been reported elsewhere [1, 13]. The extent of tumor was defined as local (confined to the thyroid gland), regional (extension into adjacent tissue or lymph node involvement), or distant (metastatic). SEER data (Nov 2012 version) was used in this study [1].

The SEER program was contacted in March 2014 and the data from 1973–2010, representing 6,981,978 cancer cases were obtained. This study selected 53,037 patients from the SEER database who were diagnosed with thyroid cancer (C73.9) as the first primary malignancy from 1988 through 2010. Only the patients with histologically confirmed papillary or follicular thyroid cancer were included. Based on the International Classification of Diseases for Oncology, Third Edition, the following histologic subclasses were included for the study: 8340 (papillary carcinoma, follicular variant), 8341 (papillary microcarcinoma), 8342 (papillary carcinoma, oxyphilic cell), 8343 (papillary carcinoma, encapsulated), 8344 (papillary carcinoma, columnar cell), 8260 (papillary adenocarcinoma, not otherwise specified), 8080 (papillary carcinoma, not otherwise specified), 8330 (follicular adenocarcinoma, not otherwise specified), 8331 (follicular adenocarcinoma, well differentiated), 8332 (follicular adenocarcinoma,
trabecular), and 8335 (follicular carcinoma, minimally invasive). Patients with incomplete information on race, surgical findings (tumor size, extent, and lymph node involvement), adjuvant therapy, survival or cause of death were excluded. Another exclusion criteria was tumor measuring 200 mm or larger. The study cohort comprised of 35,323 patients with DTC. Fig 1 details numbers of inserted and excluded patients.

Statistical analysis

For descriptive statistics, the Student $t$ test was employed for continuous variables while the chi-square test was employed for categorical variables. The Youden index $J$ was used to determine the optimal cutoff age at the times of diagnosis for predicting overall and cancer-specific cause of death. The Youden index $J$ was defined as: $J = \text{sensitivity} + \text{specificity} - 1$ [14]. Youden index $J$ in Fig 2 was derived from an univariate analysis. For the univariate assessments with dichotomous age as the predictive variable, survival curves for overall survival and cancer-specific survival were estimated using the Kaplan-Meier method and analyzed using the log-rank test. The dichotomous age points were chosen based on the Youden $J$ index results in Fig 2.

After adjusting for gender, race, size of tumor, extent, extrathyroidal extension, lymph node metastasis, distant metastasis, extent of operation, and radiation therapy, proportional hazards model was used to determine the hazard ratios (HRs) corresponding to a dichotomized age as in the multivariable model. A two-sided $P$-value < 0.05 was considered statistically significant. Survival analysis was performed using the SAS version 9.2 software (Statistical Analysis Software Institute, Cary, NC, USA), and the Youden index $J$ values were derived using the MedCalc Statistical Software version 13.1 (MedCalc Software bvba, Ostend, Belgium).

Results

Patients’ demographics and clinical characteristics are shown in Table 1. The majority of tumors were papillary thyroid cancer (93.1%). The mean age at diagnosis was 47.0 ± 15.3 years. The median follow-up period was 5.4 years (range, 0–22.9 years). During the follow-up period, overall mortality was 7.0% (n = 2,482), and thyroid cancer-specific mortality was 1.5% (n = 533).

Fig 1. Flow chart of data collection.

doi:10.1371/journal.pone.0130848.g001
The maximum Youden Index $J$ value was 0.4674 at 55 years for overall cause of death, and 0.4974 at 57 years for thyroid-cancer-specific death (Fig 2). Table 1 summarizes the distribution of demographic and clinical characteristics according to the age-at-diagnosis cutoff values for overall and thyroid-cancer-specific survival ($\leq 55, > 55$; $\leq 57, > 57$ years, respectively). Older participants were more likely to have larger tumors, lymph node metastases, and distant metastases than younger participants for both cutoff ages (all $P < 0.001$).

Kaplan-Meier survival function was evaluated for each age group for both overall survival and thyroid cancer specific survival (S1 Fig). The log-rank test demonstrated a statistically significant difference ($p < 0.001$) between both the overall survival curves, and the cancer specific survival curves based on the ages at diagnosis.

Tables 2 and 3 show the results of univariate and multivariate analysis for risk factors predictive of overall cause of death and thyroid-cancer-specific death. The cut-off ages were derived from univariate analysis (maximum Youden index $J$ at OS and DSS). The age at diagnosis was the highest risk factor for both overall cause of death and thyroid-cancer-specific death by multivariate analysis (HR 9.04, 95% confidence interval [CI] 8.26–9.90; HR 10.02, 95% CI 8.18–12.28, respectively). For overall cause of death, age at diagnosis ($> 55$ years), male gender, race (black vs. white), extrathyroidal extension, lymph node metastasis, distant metastasis, extent of operation (biopsy, lobectomy vs. total thyroidectomy), radiation therapy (radioactive I-131 ablation, external beam radiation therapy vs. no radiation therapy) were
significant predictive factors by multivariate analysis. For thyroid-cancer-specific death, age at
diagnosis (> 57 years), male gender, size of tumor, extrathyroidal extension, lymph node

Table 1. Demographics and clinical characteristics of patients with differentiated thyroid cancer
(N = 35,323).

| Characteristics                        | Number (%) |
|----------------------------------------|------------|
| Age at diagnosis, years                |            |
| Mean±SD                                | 47.0±15.3  |
| Gender                                 |            |
| Male                                   | 7,934 (22.5)|
| Female                                 | 27,389 (77.5)|
| Race                                    |            |
| Black                                  | 1,920 (5.5)  |
| White                                  | 29,261 (82.8)|
| Other                                  | 4,142 (11.7) |
| Histologic subtype                     |            |
| Papillary                              | 32,890 (93.1)|
| Follicular                             | 2,433 (6.9)  |
| Size of tumor, mm                      |            |
| Mean±SD                                | 19.3±16.3  |
| Extent of tumor                        |            |
| Localized                              | 21,952 (62.2)|
| Regional                               | 12,393 (35.1)|
| Distant*                               | 978 (2.7)   |
| Extrathyroidal extension               |            |
| Yes                                    | 5,479 (16.7) |
| No                                     | 27,411 (83.3)|
| Lymph node metastases                  |            |
| Yes                                    | 8,410 (23.8) |
| No                                     | 26,913 (76.2)|
| Distant metastases                     |            |
| Yes                                    | 978 (2.7)   |
| No                                     | 34,345 (97.3)|
| Extent of operation                    |            |
| Biopsy                                 | 244 (0.7)   |
| Lobectomy                              | 4,724 (13.4) |
| Subtotal or near-total thyroidectomy   | 2,699 (7.6)  |
| Total thyroidectomy                    | 27,655 (78.3)|
| Radiation therapy                      |            |
| No                                     | 16,448 (46.6) |
| Radioactive I-131 ablation             | 17,630 (49.9)|
| External beam radiation therapy        | 1,245 (3.5)  |
| Cause of death                         |            |
| Death resulting from thyroid cancer    | 533 (1.5)   |
| Death resulting from nonthyroid cancer | 807 (2.3)   |
| Death resulting from noncancer cause   | 1142 (3.2)  |
| Median follow-up, years                | 5.42 (0–22.9)|

*Extent of tumor: distant = distant metastases.

doi:10.1371/journal.pone.0130848.t001
metastasis, distant metastasis, extent of operation (total thyroidectomy), and postop radiation therapy were significant predictive factors based on the multivariate analysis.

**Fig 2** shows the HR distribution of age at diagnosis and its 95% CI, after adjusting for gender, race, size of tumor, extent, extrathyroidal extension, lymph node metastasis, distant metastasis, extent of operation, and radiation therapy. The Youden index J was also shown. The Youden index J and HR has similar a range of values (i.e. 50–60 years for OS and 50–58 for

---

**Table 2. Univariate and multivariate analysis of factors predictive of overall survival of patients with differentiated thyroid cancer using Cox proportional hazards model.**

| Variable                        | Univariate          | Multivariate       |
|---------------------------------|----------------------|--------------------|
|                                 | Hazard ratio (95% CI)| Hazard ratio (95% CI) |
| Age at diagnosis                |                      |                    |
| ≤ 55 yr                         | Reference            | Reference          |
| > 55 yr                         | 9.79 (8.96–10.70)    | 9.04 (8.26–9.90)   |
| Gender                          |                      |                    |
| Male                            | 2.25 (2.07–2.44)     | 1.62 (1.49–1.76)   |
| Female                          | Reference            |                    |
| Race                            |                      |                    |
| Black                           | 1.33 (1.13–1.57)     | 1.27 (1.08–1.50)   |
| White                           | Reference            | Reference          |
| Other                           | 1.07 (0.95–1.20)     | 0.93 (0.83–1.05)   |
| Size of tumor, mm               |                      |                    |
| ≤10 mm                          | Reference            | Reference          |
| >10 mm                          | 1.13 (1.03–1.23)     | 1.48 (0.95–1.16)   |
| Extent of tumor                 |                      |                    |
| Localized                       | Reference            | Reference          |
| Regional                        | 1.52 (1.40–1.65)     | 1.21 (1.06–1.37)   |
| Distant*                        | 4.20 (3.64–4.84)     | 2.67 (2.20–3.24)   |
| Extrathyroidal extension        |                      |                    |
| Yes                             | 2.51 (2.31–2.73)     | 1.59 (1.42–1.78)   |
| No                              | Reference            | Reference          |
| Lymph node metastases           |                      |                    |
| Yes                             | 1.31 (1.20–1.43)     | 1.13 (1.01–1.27)   |
| No                              | Reference            | Reference          |
| Distant metastases              |                      |                    |
| Yes                             | 3.49 (3.05–4.00)     | -\*               |
| No                              | Reference            |                    |
| Extent of operation             |                      |                    |
| Biopsy                          | 2.65 (1.97–3.55)     | 2.76 (2.05–3.71)   |
| Lobectomy                       | 1.15 (1.03–1.28)     | 1.17 (1.04–1.32)   |
| Subtotal or near total thyroidectomy | 1.11 (0.99–1.26) | 0.99 (0.88–1.12)   |
| Total thyroidectomy             | Reference            | Reference          |
| Radiation therapy               |                      |                    |
| No                              | Reference            | Reference          |
| Radioactive I-131 ablation      | 0.88 (0.81–0.95)     | 0.81 (0.74–0.89)   |
| External beam radiation therapy | 2.00 (1.73–2.32)     | 1.31 (1.12–1.53)   |

\*Extents of tumor: distant = distant metastases

Note: CI, Confidence Interval.

doi:10.1371/journal.pone.0130848.t002
DSS). The cutoff value of 55 years for overall cause of death had a sensitivity and specificity of 74.8% and 71.2% (area under curve: 0.803), respectively. The cutoff value of 57 years for thyroid-specific-death had a sensitivity and specificity of 75.8% and 73.9% (area under curve: 0.816), respectively.

### Table 3. Univariate and multivariate analysis of factors predictive of cancer-specific survival of patients with differentiated thyroid cancer using Cox proportional hazards model.

| Variables                        | Univariate Hazard ratio (95% CI) | Multivariate Hazard ratio (95% CI) |
|----------------------------------|----------------------------------|-----------------------------------|
| **Age at diagnosis**             |                                  |                                   |
| ≤ 57 yr                          | Reference                        | Reference                         |
| > 57 yr                          | 11.81 (9.71–14.35)               | 10.02 (8.18–12.28)                |
| **Gender**                       |                                  |                                   |
| Male                             | 2.46 (2.07–2.93)                 | 1.32 (1.10–1.58)                  |
| Female                           | Reference                        | Reference                         |
| **Race**                         |                                  |                                   |
| Black                            | 0.91 (0.60–1.39)                 | 0.97 (0.64–1.48)                  |
| White                            | Reference                        | Reference                         |
| Other                            | 1.32 (1.04–1.67)                 | 0.95 (0.70–1.13)                  |
| **Size of tumor, mm**            |                                  |                                   |
| ≤10 mm                           | Reference                        | Reference                         |
| >10 mm                           | 5.23 (3.82–7.17)                 | 2.50 (1.80–3.46)                  |
| **Extent of tumor**              |                                  |                                   |
| Localized                        | Reference                        | Reference                         |
| Regional                         | 7.37 (5.69–9.55)                 | 2.39 (1.71–3.34)                  |
| Distant*                         | 44.69 (33.58–59.47)              | 8.42 (5.70–12.44)                 |
| **Extrathyroidal extension**     |                                  |                                   |
| Yes                              | 10.43 (8.72–12.48)               | 2.74 (2.20–3.42)                  |
| No                               | Reference                        | Reference                         |
| **Lymph node metastases**        |                                  |                                   |
| Yes                              | 4.10 (3.45–4.86)                 | 1.65 (1.34–2.02)                  |
| No                               | Reference                        | Reference                         |
| **Distant metastases**           |                                  |                                   |
| Yes                              | 12.98 (10.72–15.72)              | -*                                |
| No                               | Reference                        | -                                 |
| **Extent of operation**          |                                  |                                   |
| Biopsy                           | 2.76 (1.52–5.03)                 | 5.46 (2.96–10.07)                 |
| Lobectomy                        | 0.52 (0.38–0.72)                 | 1.25 (0.90–1.75)                  |
| Subtotal or near total thyroidectomy | 1.12 (0.87–1.46)              | 1.16 (0.89–1.50)                  |
| Total thyroidectomy              | Reference                        | Reference                         |
| **Radiation therapy**            |                                  |                                   |
| No                               | Reference                        | Reference                         |
| Radioactive I-131 ablation       | 2.14 (1.74–2.63)                 | 1.16 (0.93–1.45)                  |
| External beam radiation therapy  | 10.33 (8.03–13.27)               | 3.04 (2.33–3.97)                  |

*Extent of tumor: distant = distant metastases

Note: CI, Confidence Interval.

doi:10.1371/journal.pone.0130848.t003
Discussion

The purpose of this population-based cohort study was to evaluate age at the time of diagnosis and that might be most optimal for predictive the clinical outcome in DTC. A total of 35,323 patients with DTC from 1988–2010 were selected with clinicopathologic information from the SEER cancer database. For patients with DTC, age at diagnosis was the most important predictive factor for death from thyroid cancer (55 years: HR 10.02, 95% CI 8.18–12.28), and overall cause of death (57 years: HR 9.04, 95% CI 8.26–9.90) based on the multivariate analysis using the Cox proportional hazards models.

Prognosis of majority of DTCs are excellent, however, about 10% of patients eventually die of the disease [15–17]. Therefore, a number of studies have tried to establish a risk stratification system or staging system to classify high-risk and low-risk patients based on demographic, and clinicopathologic factors. In DTC, age at diagnosis is considered to be a strong prognostic factor and, therefore, it is integrated in the majority of staging systems [3–10,18,19]. The tumor, node, metastases (TNM) staging system [3] developed jointly by the Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC), classifies DTC patients using a cutoff value of 45 years for age at diagnosis. Other staging systems such as Age, Metastases, Extent, Size (AMES) [4]; Grade, Age, Metastases, Extent, Size (GAMES) [5]; Noguchi et al. [6]; and the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) [7] have adopted a similar age-based staging system using diverse cutoff values for age to risk-stratify patients with DTC. In contrast, the systems used by the following: European Organization for Research and Treatment of Cancer (EORTC) [8]; Age, Grade, Extent, Size (AGES) [9]; and Metastasis, Age, Completeness of Resection, Invasion, Size (MACIS) [10] systems have adopted the age factor as a continuous variable for calculating prognostic scores.

While age is generally considered as an important determinant of clinical outcome for DTC, an optimal cutoff age has not been well established. The present study tried to find an optimal cut-off point with Youden index $J$ which will reflect the maximum area under curve (AUC). The specific ages (age at 55 for OS, and 57 for DSS) were likely to have maximum Youden index $J$, however, it was derived with univariate results. Therefore, further prospective and well-designed research for suggesting proper age cut-off levels should be followed.

Interestingly, these finding are similar to those of recent studies [11,20]. Jonklass et al [11] suggested a cutoff value based on the age when most women attained menopause [21,22], and hypothesized that the age of 55 was appropriate for DTC staging systems using the Cox proportional hazard model after adjusting for age at diagnosis, gender, and TNM stage. Mazurat [20] divided study group into small age groups to find optimal cutoff value of age and also suggested that 55 years is better than 45 years for risk stratification in DTC patients using multivariate Cox proportional hazard model. Therefore, results of our study could be useful for redefining the existing staging systems for DTC. Nevertheless, controversies exist with advocates for both increased and decreased cut-off age for prognosis. Of note, Tran Cao et al [23] found that starting at age 30, each age decade was independently associated with a worse prognosis. Furthermore, Bischoff et al [24] found that 5-year survival decreased in each age category with 5-year increment without an inflection point at age 45 for papillary thyroid cancer.

Recently, using the SEER database, Yang et al. [13] analyzed 29,225 patients with thyroid cancers of all subtypes, and developed a nomogram based on a competing risk model to predict probability of death in thyroid cancer patients. Since most DTC patients have an indolent course with a low mortality rate, analyzing the probability of cancer-specific death can be challenging. Unlike the single-institution-based study [12], the population-based SEER cancer database has allowed simultaneous examination of a number of prognostic factors in a large
group of patients who were not subjected to selection or referral biases [18]. A population-based cohort study can depict more reliable, and generally applicable information [13].

Therefore, we believe that this study provides generally acceptable information for healthcare providers and patients, regarding the effect of age at the time of diagnosis and DTC. The results of this study would be helpful to identify at-risk patients for DTC and guide treatment plans, including the extent of operative management as well as postoperative radioactive iodine therapy, and follow-up.

Although we analyzed the population-based cohort and used multivariate analyses to account for confounding factors, this study has some limitations. We could not determine the risk factors for DTC recurrence using the SEER database, or determine whether the age at diagnosis is also an important predictor of DTC recurrence. Because the SEER database focuses on gathering reliable information during the diagnostic period often without a mortality data, little information were collected on later events [25]. All models are main effect models, therefore, our method of Youden index analysis may not have accounted for the other prognostic factors related to age. In addition, we could not confirm that the cutoff age of 57 for DTC-specific death was a better predictor than the cutoff age of 45 used in the TNM staging system. This is due to the fact that the SEER database prior to 2004 lacks, any information on thyroid cancer TNM staging including the lymph node metastasis status such as central lymph node metastases (N1a) vs. lateral lymph node metastases (N1b).

Conclusions

In conclusion, this study found that the age-at-diagnosis is the most important prognostic factor for patients with DTC and the age cutoff value of 57 years may better risk stratify and predict the cancer-specific death for DTC patients. This finding might be used as consideration in revision of the risk stratification system for treatment of DTC patients.

Supporting Information

S1 Fig. Survival curve for overall survival and thyroid cancer specific survival by age cut-off levels.
(TIF)

S1 Table. Demographic and clinical characteristics of patients with differentiated thyroid cancer according to cutoff ages at diagnosis.
(DOCX)

Author Contributions

Conceived and designed the experiments: SJK JPM. Analyzed the data: JPM SJK. Contributed reagents/materials/analysis tools: JPM SJK. Wrote the paper: SJK JPM HSS KEL YKY.

References

1. National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results Program. Available: www.seer.cancer.gov. Accessed 28 December 2014.
2. Pellegriti G, Frasca F, Regalbuto C, Sebastiano S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212 doi: 10.1155/2013/965212 PMID: 23737785
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Handbook, 7th edition. New York: Springer-Verlag. 87–96p.
4. Cady B & Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953. PMID: 3194846
5. Shaha AR, Loree TR, Shah JP (1994) Intermediate-risk group for differentiated carcinoma of the thyroid. Surgery 116:1036–1041. PMID: 7985084

6. Noguchi S, Murakami N, Kawamoto H (1994) Classification of papillary cancer of the thyroid based on prognosis. World J Surg 18:552–558. PMID: 7725744

7. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, et al. (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer 83:1012–1021. PMID: 9731906

8. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, et al. (1979) A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15:1033–1041. PMID: 8256208

9. Hay ID, Grant CS, Taylor WF, McConahey WM (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095. PMID: 3686348

10. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058. PMID: 8256208

11. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, et al. (2012) The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97:E878–887. doi: 10.1210/jc.2011-2864 PMID: 22496497

12. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A (2014) Prognostic significance of young age in papillary thyroid carcinoma: analysis of 5,733 patients with 150 months' median follow-up. Endocr J 61:491–497. PMID: 24553476

13. Yang L, Shen W, Sakamoto N (2013) Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol 31:468–474. doi: 10.1200/JCO.2012.42.4457 PMID: 23270002

14. Schisterman EF, Perkins NJ, Liu A, Bondell H (2005) Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 16:73–81 PMID: 15613948

15. Sherman SI (2003) Thyroid carcinoma. Lancet 361:501–511. PMID: 12583960

16. Mazzaferri EL, Kloos RT (2001) Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463. PMID: 11297567

17. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, et al. (2006) Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:313–319. PMID: 16263822

18. Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573. PMID: 9028369

19. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the U.S., 1985–1995. Cancer 83:2638–48. PMID: 9874474

20. Mazurat A, Torroni A, Hendrickson-Rebizant J, Benning H, Nason RW, Pathak KA (2013) The age factor in survival of a population cohort of well-differentiated thyroid cancer. Endocr Connect 2:154–160. doi:10.1530/EC-13-0056 PMID: 24083939

21. Weinstein M, Gorrindo T, Riley A, Mormino J, Singer B, et al. (2003) Timing of menopause and patterns of menstrual bleeding. Am J Epidemiol 158:782–791. PMID: 14561668

22. McKinlay SM, Bremilla DJ, Posner JG (1992) The normal menopause transition. Maturitas 14:103–115. PMID: 1565019

23. Tran Cao HS, Johnston LE, Chang DC, Bouvet M (2012) A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry. Surgery 152(2):145–151. doi: 10.1016/j.surg.2012.02.015 PMID: 22503316

24. Bischoff LA, Curry J, Ahmed I, Pribitkin E, Miller JL (2013) Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract 19(6):995–997. doi: 10.4158/EP13029.OR PMID: 24013977

25. In H, Bilimoria KY, Stewart AK, Wroblewski KE, Posner MC, Talamonti MS, et al. (2014) Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol 21:1520–1529. doi: 10.1245/s10434-014-3516-x PMID: 24504926